Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 12/20 | 0.47 |
| ▸ | HRH1 | P35367 | 12/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25502988 | 0.99 | HRH2 (0.48) | HRH2HRH1CHRM3STSCA2 | |
| SCHEMBL25500680 | 0.95 | HRH2 (0.47) | HRH2HRH1CHRM3OPRK1 | |
| SCHEMBL25499345 | 0.86 | HRH2 (0.42) | HRH2HRH1OPRK1 | |
| SCHEMBL25499344 | 0.84 | HRH2 (0.43) | HRH2HRH1OPRK1 | |
| SCHEMBL26040761 | 0.80 | HRH2 (0.49) | HRH2HRH1CHRM3GNAI3GNAO1 | |
| SCHEMBL26039937 | 0.80 | GNAI3 (0.45) | GNAI3GNAO1GNAI1OPRK1 | |
| SCHEMBL17313867 | 0.78 | DPP7 (0.49) | HRH2HRH1CHRM3GNAI3GNAO1 | |
| SCHEMBL17313872 | 0.78 | DPP7 (0.49) | HRH2HRH1CHRM3GNAI3GNAO1 | |
| SCHEMBL17313869 | 0.78 | DPP7 (0.49) | HRH2HRH1CHRM3GNAI3GNAO1 | |
| SCHEMBL25500682 | 0.78 | GNAI3 (0.43) | GNAI3GNAO1GNAI1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | FIBP, FGFR2, FGFR1 | HRH2 3821/4885HRH1 2968/4885CHRM3 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.